It was recently published in the International Journal of Ophthalmology a systematic review of the literature that compares the efficacy and safety of bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD). Zhang and his colleagues collected data from 4 randomized clinical trials (RCTs) and 11 observational studies, for a total number of more than 4,000 patients. They concluded that the effectiveness of treatments is similar, but that ranibizumab is safer than bevacizumab .